

Mounting research shows that COVID-19 leaves its mark on the brain, including with significant drops in IQ scores

Thursday 29 February 2024, by [Al-ALY Ziyad](#) (Date first published: 28 February 2024).

Contents

- [How COVID-19 leaves its \(...\)](#)
- [Drops in IQ](#)
- [Parsing the implications](#)

Research shows that even mild COVID-19 can lead to the equivalent of seven years of brain aging. Victor Habbick Visions/Science Photo Library via Getty Images

From the very early days of the pandemic, [brain fog emerged as a significant health condition](#) that many experience after COVID-19.

Brain fog is a colloquial term that describes a state of mental sluggishness or lack of clarity and haziness that makes it difficult to concentrate, remember things and think clearly.

Fast-forward four years and there is now abundant evidence that being infected with SARS-CoV-2 - the virus that causes COVID-19 - [can affect brain health in many ways](#).

In addition to brain fog, COVID-19 can lead to [an array of problems](#), including headaches, seizure disorders, strokes, sleep problems, and tingling and paralysis of the nerves, as well as [several mental health disorders](#).

A large and growing body of evidence amassed throughout the pandemic details the many ways that [COVID-19 leaves an indelible mark](#) on the brain. But the specific pathways by which the virus does so are still being elucidated, and curative treatments are nonexistent.

Now, two new studies published in the New England Journal of Medicine shed further light on the [profound toll of COVID-19 on cognitive health](#).

I am a [physician scientist](#), and I have been devoted to studying [long COVID](#) since early patient reports about this condition - even before the term "long COVID" was coined. I have testified before the U.S. Senate as [an expert witness on long COVID](#) and have [published extensively](#) on this topic.

How COVID-19 leaves its mark on the brain

Here are some of the most important studies to date documenting how COVID-19 affects brain health:

- Large epidemiological analyses showed that people who had COVID-19 were at an [increased risk](#)

[of cognitive deficits](#), such as memory problems.

- Imaging studies done in people before and after their COVID-19 infections show [shrinkage of brain volume](#) and [altered brain structure after infection](#).
- A study of people with mild to moderate COVID-19 showed significant prolonged inflammation of the brain and [changes that are commensurate with seven years of brain aging](#).
- Severe COVID-19 that requires hospitalization or intensive care may result in cognitive deficits and other brain damage that are [equivalent to 20 years of aging](#).
- Laboratory experiments in human and mouse brain [organoids](#) designed to emulate changes in the human brain showed that SARS-CoV-2 infection triggers the [fusion of brain cells](#). This effectively short-circuits brain electrical activity and compromises function.
- Autopsy studies of people who had severe COVID-19 but died months later from other causes showed that [the virus was still present in brain tissue](#). This provides evidence that contrary to its name, SARS-CoV-2 is not only a respiratory virus, but it can also enter the brain in some individuals. But whether the persistence of the virus in brain tissue is driving some of the brain problems seen in people who have had COVID-19 is not yet clear.
- Studies show that even when the virus is mild and exclusively confined to the lungs, it can still provoke inflammation in the brain and [impair brain cells' ability to regenerate](#).
- COVID-19 can also [disrupt the blood brain barrier](#), the shield that protects the nervous system - which is the control and command center of our bodies - making it "leaky." Studies using imaging to assess the brains of people hospitalized with COVID-19 showed disrupted or leaky blood brain barriers in those who experienced brain fog.
- A large preliminary analysis pooling together data from 11 studies encompassing almost 1 million people with COVID-19 and more than 6 million uninfected individuals showed that COVID-19 [increased the risk of development of new-onset dementia](#) in people older than 60 years of age.

Autopsies have revealed devastating damage in the brains of people who died with COVID-19

Drops in IQ

Most recently, a new study published in the New England Journal of Medicine [assessed cognitive abilities](#) such as memory, planning and spatial reasoning in nearly 113,000 people who had previously had COVID-19. The researchers found that those who had been infected had significant deficits in memory and executive task performance.

This decline was evident among those infected in the early phase of the pandemic and [those infected when the delta](#) and [omicron variants](#) were dominant. These findings show that the risk of cognitive decline did not abate as the pandemic virus evolved from the ancestral strain to omicron.

In the same study, those who had mild and resolved COVID-19 showed cognitive decline equivalent to a three-point loss of IQ. In comparison, those with unresolved persistent symptoms, such as people with persistent shortness of breath or fatigue, had a six-point loss in IQ. Those who had been admitted to the intensive care unit for COVID-19 had a nine-point loss in IQ. Reinfection with the virus contributed an additional two-point loss in IQ, as compared with no reinfection.

Generally the average IQ is about 100. An IQ above 130 indicates a highly gifted individual, while an IQ below 70 generally indicates a level of intellectual disability that may require significant societal support.

To put the finding of the New England Journal of Medicine study into perspective, I estimate that a three-point downward shift in IQ would increase the number of U.S. adults with an IQ less than 70 from 4.7 million to 7.5 million – an increase of 2.8 million adults with a level of cognitive impairment that requires significant societal support.

Another study in the same issue of the New England Journal of Medicine involved more than 100,000 Norwegians between March 2020 and April 2023. It [documented worse memory function](#) at several time points up to 36 months following a positive SARS-CoV-2 test.

Parsing the implications

Taken together, these studies show that COVID-19 poses a serious risk to brain health, even in mild cases, and the effects are now being revealed at the population level.

A recent analysis of the [U.S. Current Population Survey](#) showed that after the start of the COVID-19 pandemic, an [additional 1 million working-age Americans](#) reported having “serious difficulty” remembering, concentrating or making decisions than at any time in the preceding 15 years. Most disconcertingly, this was mostly driven by younger adults between the ages of 18 to 44.

Data from the European Union shows a similar trend – in 2022, 15% of people in the EU [reported memory and concentration issues](#).

Looking ahead, it will be critical to identify who is most at risk. A better understanding is also needed of how these trends might affect the educational attainment of children and young adults and the economic productivity of working-age adults. And the extent to which these shifts will influence the epidemiology of dementia and Alzheimer’s disease is also not clear.

The growing body of research now confirms that COVID-19 should be considered a virus with a significant impact on the brain. The implications are far-reaching, from individuals experiencing cognitive struggles to the potential impact on populations and the economy.

Lifting the fog on the true causes behind these cognitive impairments, including brain fog, will require years if not decades of concerted efforts by researchers across the globe. And unfortunately, nearly everyone is a test case in this unprecedented global undertaking.

[Ziyad Al-Aly](#), Chief of Research and Development, VA St. Louis Health Care System. Clinical Epidemiologist, [Washington University in St. Louis](#)

<http://theconversation.com/republishing-guidelines> —>

P.S.

- The Conversation. Publié: 28 février 2024, 23:42 CET.

This article is republished from [The Conversation](#) under a Creative Commons license. Read the [original article](#).

- Dr. Al-Aly a physician-scientist; he directs the Clinical Epidemiology Center and serves as the Chief of Research and Development Service at the VA Saint Louis Health Care System. He is a senior clinical epidemiologist at Washington University in Saint Louis. He has several research interests including pharmacoepidemiology, environmental epidemiology, global health, and most recently short- and long-term effects of COVID-19 on health outcomes.

He led work which provided systematic characterization of the post-acute sequelae of SARS-CoV-2 infection (also called Long Covid) and subsequently characterization of the increased risks of cardiovascular disease, neurologic disorders, diabetes, dyslipidemia, kidney disease, and gastrointestinal disorders following SARS-CoV-2 infection. His laboratory was the first to produce evidence characterizing the effects of vaccines on Long Covid, the health consequences of repeated infections with SARS-CoV-2, and the effect of antivirals on the short- and long-term outcomes of SARS-CoV-2 infection.

Dr. Al-Aly co-chaired the U.S. Biden-Harris Administration committee that developed the National Research Action Plan for Long Covid. He serves on the US Government Interagency Long Covid Coordination Council. He advised the Chief Science Advisor of Canada (Mona Nemer - Government of Justin Trudeau) on Long Covid strategy. He currently serves on a consensus committee at the U.S. National Academy of Sciences, Engineering, and Medicine looking at the long-term health effects stemming from COVID-19 and their implications for the U.S. Social Security Administration. He is also a member of the White House Cancer Moonshot Task Force for data and innovation.

Dr. Al-Aly's work is published in prestigious medical journals including Nature, Nature Medicine, the New England Journal of Medicine, the British Medical Journal, the Journal of the American Medical Association, the Lancet and several others [...]

- The Conversation is a nonprofit news organization dedicated to helping academic experts share ideas with the public. We can give away our articles thanks to the help of foundations, universities and readers like you. [Donate Now to support research-based journals](#)